Tatiana Novobrantseva

Chief Scientific Officer · NextPoint Therapeutics

Tatiana Novobrantseva is the Chief Scientific Officer at NextPoint Therapeutics. Most recently she served as the CSO of Immuno-oncology at Moderna. In the prior role, she co-founded Verseau Therapeutics and served as CSO, guiding programs from target identification to an advanced novel therapeutics pipeline. Tatiana also consulted on drug development program for various companies throughout the years. At Jounce, she directed programs on immune system reactivation against cancer. Tatiana held roles at Alnylam and Biogen, uncovering the critical role of B cells in fibrosis, advancing siRNA delivery, and leading a dendritic cell cancer vaccine initiative. She earned her Ph.D. in B cell immunology from the University of Cologne in Germany in the Laboratory of Klaus Rajewsky. She holds a Diploma in Engineering in Physics and a Master’s degree in Molecular Biology from the Moscow Institute of Physics and Technology.

Is this you? Claim this profile →